论文部分内容阅读
目的 观察肾移植患者应用他克莫司 (FK50 6 )进行免疫抑制治疗的效果和副作用。方法 对肾移植术后应用FK50 6的 6 4例患者的临床资料进行回顾性分析。结果 肾移植术后即应用FK50 6、霉酚酸酯 (MMF)及泼尼松的 2 4例患者 ,术后未发生急性排斥反应 ;先用环孢素A ,后因肝功能异常、急性排斥反应及慢性排斥反应而改用FK50 6的 4 0例患者 ,大部分排斥缓解 ,肝功能改善 ;FK50 6的主要副作用有血糖升高 ( 1 0 .9% )和肾毒性 ( 4 .7% )。结论 FK50 6是一种强效的免疫抑制剂 ;其用量的个体差异很大。
Objective To observe the effects and side effects of immunosuppressive therapy with tacrolimus (FK50 6) in renal transplant recipients. Methods The clinical data of 64 patients with FK506 after renal transplantation were retrospectively analyzed. Results Fourteen patients with FK50 6, mycophenolate mofetil (MMF) and prednisone after renal transplantation did not have any acute rejection after surgery. Cyclosporin A was used first and then acute rejection due to liver dysfunction Response and chronic rejection of 40 patients switched to FK506, most of the exclusion of remission, improved liver function; FK506 main side effects of elevated blood glucose (1.09%) and nephrotoxicity (4.7%) . Conclusions FK50 6 is a potent immunosuppressive agent; its individual dosage varies widely.